ABL1 and acute lymphoblastic leukemia: Tyrosine kinase inhibitors (TKIs) which target BCR-ABL, such as imatinib, dasatinib and ponatinib, have resulted in durable cytogenetic and molecular remissions in most CML patients and increased remission rates in Ph+ ALL patients [21].